

Pediatric COVID-19 Vaccine Dosing Quick Reference Guide





Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Moderna COVID-19 Vaccine Products 2026–2027 Formula			Pfizer-BioNTech COVID-19 Vaccine Products 2026–2027 Formula		Novavax COVID-19 Vaccine Product 2026–2027 Formula
Spikevax (red label) 6 months–11 years  0.25 ml single-dose prefilled syringe	Spikevax (blue label) 12 years and older  0.5 ml single-dose prefilled syringe	mNEXSPIKE (teal label) 12 years and older  0.2 ml single-dose prefilled syringe	Comirnaty (blue cap) 5–11 years  10 mcg/0.3 ml single-dose vial	Comirnaty (gray label) 12 years and older  0.3 ml single-dose prefilled syringe	Nuvaxovid (dark cyan label) 12 years and older  0.5 ml single-dose prefilled syringe



^a For children who turn 2 during their vaccine series, complete the initial series using the recommended schedule as outlined for individuals 6–23 months.


^b An 8-week interval between the first and second COVID-19 vaccine doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these vaccines.

Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products for Individuals who are Moderately or Severely Immunocompromised

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age on the day of vaccination.

b. Individuals who are moderately or severely immunocompromised should receive one additional age-appropriate dose of 2026–2027 COVID vaccine from any manufacturer 6 months following the last recommended 2026–2027 dose (minimum interval 2 months).

c. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit; (2) Previous dose unknown; (3) Person would otherwise not receive a recommended vaccine dose; (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A [Vaccine Adverse Event Reporting System \(VAERS\)](#) report is not indicated in these circumstances.

d. Individuals who are moderately or severely immunocompromised may receive further additional doses at ≥2 month intervals, informed by clinical judgment of a healthcare provider and personal preference and circumstances. Individuals 5 years and older may receive any age-appropriate 2026–2027 COVID vaccine for all additional doses, regardless of manufacturer for the initial series.

e. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.